Abstract
Mutations at both the receptor-binding domain (RBD) and the amino (N)-terminal domain (NTD) of the SARS-CoV-2 Spike (S) glycoprotein can alter its antigenicity and promote immune escape. We identified that SARS-CoV-2 lineages circulating in Brazil with mutations of concern in the RBD independently acquired convergent deletions and insertions in the NTD of the S protein, which altered the NTD antigenic-supersite and other predicted epitopes at this region. These findings support that the ongoing widespread transmission of SARS-CoV-2 in Brazil is generating new viral lineages that might be more resistant to neutralization than parental variants of concern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support was provided by FAPEAM (PCTI EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude REGESAM); Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Ministerio da Saude MS/FNDCT/SCTIE/Decit (grants 402457/20209 and 403276/20209); Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB 007 FIO18230 and VPPCB 005FIO20287) and INCT FCx (465259/2014-6). Computer allocation was partly granted by the Brazilian National Scientific Computing Center (LNCC). FGN, GLW, RDL and GB are supported by the CNPq through their productivity research fellowships (306146/20177, 303902/20191, 425997/20189 and 302317/20171 respectively). G.B. is also funded by the Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro FAPERJ (Grant number E 26/202.896/2018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the FIOCRUZ-IOC (68118417.6.0000.5248 and CAAE 32333120.4.0000.5190) and the Amazonas State University Ethics Committee (CAAE: 25430719.6.0000.5016) and the Brazilian Ministry of the Environment (MMA) A1767C3.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All genome sequences used in this study were deposited in GISAID and corresponding IDs can be found in the manuscript.
